Chiasma — Investor Presentation (April 2019)
29 slides from Chiasma's investor presentation, Apr 8, 2019
Slide 1: Chiasma Overview
Chiasma Overview APRIL 2019 NASDAQ: CHMA Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are i
Slide 3: CHMA Investment Highlights
CHMA Investment Highlights Rare and Orphan Disease Focus Clinically Advanced Lead Asset Lead program targeting adults with acromegaly Octreotide capsules (Mycapssa®), if approved, positioned to become the first oral somatostatin analog in an injectable-only market Encouraging Phase 3 safety and effi
Slide 4: Acromegaly: A Rare and Debilitating Hormonal Disorder
Acromegaly: A Rare and Debilitating Hormonal Disorder Caused by excessive secretion of growth hormone (GH) stemming from a benign pituitary tumor that leads to an excess of insulin-like growth factor-1 (IGF-1) ~69,000* patients worldwide Features include enlarged hands, feet and internal organs, alt
Slide 5: Current Injection Therapies Carry Treatment Burdens
Current Injection Therapies Carry Treatment Burdens* Emotional Impact 36% feel loss of independence due to chronic injections Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammation (7%) Lost Work Days 16% regularly miss work for injections (averages 1
Slide 6: $2.7 Billion Global Market for Somatostatin Analogs (SSA)
$2.7 Billion Global Market for Somatostatin Analogs (SSA) 1. Financial reports and filings, Novartis & Ipsen, 2016–2018. We estimate acromegaly is ~$810M annually — A significant potential market opportunity for Chiasma Octreotide (63%) 2018 Share by Analog Type1 Global Injectable Somatostatin Analo
Slide 7: U.S. Acromegaly Treatment Reimbursement Landscape
U.S. Acromegaly Treatment Reimbursement Landscape Weighted average cost for mid-range doses annually as provided by Red Book Online (Dec 15, 2015; Feb 02, 2019 ) rounded to nearest $1k Tag & Associates, Inc. Dec 2018. Based on published medical and drug coverage policies of United Healthcare, Anthem
Slide 8: If Approved, We Expect Significant Demand for Mycapssa
If Approved, We Expect Significant Demand for Mycapssa % of patients who would prefer oral therapy Monthly IM Octreotide LAR Monthly Depot SC lanreotide 3x Daily SC Octreotide IR 1. Chiasma sponsored research: Acromegaly Medication Preferences, 2010, Market Modeler LLC, NJ 2. Per protocol, all patie
Slide 9: Orphan, Addressable U.S. Acromegaly Market Opportunity
Orphan, Addressable U.S. Acromegaly Market Opportunity 1.Endocrinology market studies. 2.Company estimates Sizing the Acromegaly Market Addressing the Market Cured through surgery Not treated with SSAs Chronically treated with SSA injections ~14,0001 ~8,0002 ~2,0002 # of U.S. Patients Diagnosed Acro
Slide 10: U.S. Mycapssa Exclusivity Timeline
U.S. Mycapssa Exclusivity Timeline* JUNE 2020* Market Entry JUNE 2027 Expiration of Orphan Exclusivity SEPTEMBER 2029 Expiration of Formulation Patent FEBRUARY 2036 Expiration of Allowed Dosing Patent Application (NEW) End of Patent Exclusivity JUNE 2023 Expiration of New Clinical Investigation Excl
Slide 11: Established Acromegaly SSA Injections Market in E.U.
Established Acromegaly SSA Injections Market in E.U. Acromegaly sales >$300M in 2016 Annual pricing: Germany $25K Switzerland $22K France $17K UK $13K Injections reimbursed across European Union Acromegaly guidelines and treatment options similar to U.S. Injection administration takes place mainly i
Slide 12: Key Expected Milestones
Key Expected Milestones CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019, if positive, will support planned U.S. NDA resubmission by year end 2019; 6-month NDA review classification expected; Focused U.S. commercial readiness planning underway MPOWERED (302) Study Planned NDA submission CHIA
Slide 13: TPE Delivery Platform for Certain Oral Peptide Therapies
TPE® Delivery Platform for Certain Oral Peptide Therapies …then absorbed intact at therapeutic levels. Peptide is protected by TPE® from degradation… TPE enhances oral bioavailability, potentially allowing for oral formulations of injectable-only therapies
Slide 14: Bioavailability of Oral Octreotide Is Comparable to SC Injection
Bioavailability of Oral Octreotide Is Comparable to SC Injection Data are mean ± SEM. * Octreotide subcutaneous (SC) injection = Sandostatin®, IR injection, Novartis. Octreotide SC (n=14) Octreotide Capsule (n=24) AUC(0-inf) (h´ng/mL) 13.7 (2.29) 17.0 (9.66) t1/2 (h) 2.27 (0.25) 2.66 (0.73) Data are
Slide 15: Phase 1 Data Strongly Supported Further Development
Phase 1 Data Strongly Supported Further Development Phase 1 study in 16 healthy subjects; cross-over design Tuvia S et al. J Clin Endocrinol Metab. 2012. Dosing Initiated No Treatment Data are Mean ± SE Time (hr) Growth Hormone (ng/mL) Octreotide capsules Significant growth hormone (GH) inhibition r
Slide 16: CH-ACM-01 Phase 3 Trial Design
CH-ACM-01 Core Extension Screening Baseline Day (-14) First Dose Day 0 13 mo. 7 mo. Last Injection Day (-28) Patient choice to continue on oral Titration phase Baseline period on injections N=151 N=110 N=88 N=82 N=102 N=155 2x daily Discontinuation (N=49): Treatment Failure (24), AE (18), Other (7)
Slide 17: CH-ACM-01 Primary Endpoint and Safety Results
CH-ACM-01 Primary endpoint defined as biochemical response (GH <2.5 ng/ml and IGF-1 <1.3 x ULN) at 7 months Pituitary experts specified a population response ≥50% for a positive prescription decision 75% of the patients who completed dose escalation showed biochemical control Safety profile of octre
Slide 18: Biochemical Response to Octreotide Capsules
CH-ACM-01 2.5 2.0 1.5 1.0 0.5 0 7 mo. + End Dose Esc. + First Dose + Baseline + IGF-1 X ULN IGF-1 + 13 mo. 3.0 2.5 2.0 1.5 1.0 0.5 Baseline + First Dose + + + 13 mo. GH ng/mL Growth Hormone 0 + Response <1.3xULN Response <2.5 ng/mL End Dose Esc. 7 mo. Responder Non-Responder Melmed S et al. J Clin E
Slide 19: CH-ACM-01 Symptom Response
CH-ACM-01 80% of patients reported symptoms entering the trial Reduced incidence of symptoms reported in responders on octreotide capsules 80% of patients who entered fixed-dose portion of trial reported improved or maintained acromegaly symptom response at end of treatment Reduced breakthrough symp
Slide 20: CHIASMA OPTIMAL: Under Phase 3 SPA Agreement With FDA
CHIASMA OPTIMAL: Under Phase 3 SPA Agreement With FDA Chiasma received a CRL from FDA in April 2016 NDA (filed in 2015) did not provide substantial evidence of efficacy to warrant approval Concerns regarding certain aspects of the single-arm, open-label Phase 3 clinical trial Randomized, double-blin
Slide 21: CHIASMA OPTIMAL Trial Design
CHIASMA OPTIMAL Open Label Extension Double-blind placebo-controlled (DPC) (36 weeks) Eligibility criteria: Average IGF-1 ≤1.0 ´ ULN Confirm active disease (IGF-1≥1.3xULN post last surgery) Primary Endpoint: Proportion of patients who maintain biochemical response at end of DPC period (average of la
Slide 22: Octreotide Capsules E.U. Regulatory Status
Octreotide Capsules E.U. Regulatory Status MPOWERED Phase 3 protocol accepted by the EMA EMA has granted octreotide capsules orphan status Planning to leverage the EMA’s hybrid application pathway Up to 150 patient trial initiated in March 2016 135 patients entered six-month run-in phase by July 201
Slide 23: MPOWERED: Phase 3 Trial Design
MPOWERED: Phase 3 Trial Design Primary Endpoint: Proportion of patients who are biochemically controlled throughout the RCT phase. Key Secondary Endpoints: Proportion of patients who are biochemically controlled at the end of RCT Proportion of patients who maintain or reduce the overall number of ac
Slide 24: Q4-2018 Financial Overview
Q4-2018 Financial Overview $32.2 million in net proceeds raised from common stock offering in April 2019 Cash expected to be sufficient to fund our operations as currently planned through CHIASMA OPTIMAL top-line data and, if positive, through our anticipated mid-2020 PDUFA date and into late 2020 F
Slide 25: Experienced Management
Experienced Management Management Team Role Prior Affiliations Mark Fitzpatrick President, Chief Executive Officer 2019 OPENING SR. COMMERCIAL LEADER William Ludlam, M.D. Ph.D. SVP, Clinical/Medical Affairs Gary Patou, M.D. Head of Clinical Shoshie Katz VP, Regulatory and Quality Dana Gelbaum VP, Gl
Slide 26: Experienced Board
Experienced Board Board of Directors Key Current / Prior Affiliations Dave Stack, Chairman Mark Fitzpatrick Todd Foley Bard Geesaman, M.D. Ph.D. . Roni Mamluk, PhD, former CDO & CEO Scott Minick John (Chip) Scarlett, M.D. John Thero Ayala Board experienced in drug development and commercialization
Slide 27: Representative CHMA Investor Base
Representative CHMA Investor Base – (12/31/18 and prior filings) ROCK SPRINGS CAPITAL
Slide 28: CHMA Investment Highlights
CHMA Investment Highlights Rare and Orphan Disease Focus Clinically Advanced Lead Asset Lead program targeting adults with acromegaly Octreotide capsules (Mycapssa®), if approved, positioned to become the first oral somatostatin analog in an injectable-only market Encouraging Phase 3 safety and effi
Slide 29: Thank you
Thank you APRIL 2019 NASDAQ: CHMA